A New Horizon in Cancer Treatment: Alpha Tau Commences U.S. Pancreatic Cancer Clinical Trial with First Patient Treated

In a momentous stride forward for oncology, Alpha Tau Medical, a clinical-stage oncology company dedicated to developing innovative alpha-radiation-based cancer therapies, has announced the successful treatment of the first patient in its U.S. multi-center clinical trial for pancreatic cancer. This pivotal milestone signifies a new chapter in the fight against one of the most aggressive and challenging cancers, bringing the company's proprietary Alpha-DART (Diffusing Alpha-emitters Radiation Therapy) technology closer to becoming a viable treatment option.

Pancreatic cancer is notoriously difficult to diagnose early and treat effectively, often presenting at advanced stages with limited therapeutic avenues and a grim prognosis.

The urgent need for novel, more potent treatments has long been a top priority for researchers and clinicians worldwide. Alpha Tau's Alpha-DART technology offers a beacon of hope, providing a localized, high-precision radiation therapy that delivers powerful alpha-emitters directly to tumor sites.

The Alpha-DART system involves implanting tiny wires containing Radium-224 into the tumor.

As Radium-224 decays, it releases short-lived alpha-emitting daughters that diffuse a short distance, delivering highly potent, localized radiation. Unlike traditional radiation therapies, alpha particles are significantly more effective at inducing irreparable DNA damage in cancer cells, while their limited range helps spare surrounding healthy tissue.

This targeted approach aims to overcome the limitations of conventional treatments, offering a more effective and less toxic option for patients.

The current U.S. multi-center trial is designed to evaluate the safety and efficacy of the Alpha-DART technology in patients with locally advanced pancreatic cancer.

The successful treatment of the inaugural patient represents a critical step in gathering robust clinical data and advancing the trial towards its objectives. This achievement underscores Alpha Tau's commitment to transforming cancer care and its ongoing dedication to scientific innovation.

Uzi Hadar, CEO of Alpha Tau, remarked on this significant development: "Treating the first patient in our U.S.

pancreatic cancer trial is a profound moment for Alpha Tau and a testament to years of dedicated research and development. Pancreatic cancer patients desperately need new solutions, and we believe our Alpha-DART technology holds immense promise. This is a crucial step in bringing a potentially life-changing therapy to those who need it most, and we look forward to the continued progress of this vital study."

The initiation of patient treatment in the U.S.

trial builds upon positive results observed in earlier studies, demonstrating the technology's potential across various solid tumors. With each patient treated, Alpha Tau moves closer to validating Alpha-DART as a transformative intervention for pancreatic cancer, offering renewed hope and a potentially brighter future for countless individuals battling this devastating disease.

The medical community and patient advocates are closely watching the progress of this trial, as the successful deployment of Alpha-DART could herald a new era in precision oncology, fundamentally altering the treatment landscape for pancreatic cancer and potentially other challenging malignancies.